Point72 Hong Kong LTD Jounce Therapeutics, Inc. Transaction History

Point72 Hong Kong LTD

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.73 - $4.92 $5,009 - $9,028	-1,835 Reduced 83.79%	355 $1,000
Q3 2022 Nov 14, 2022	SELL	$2.73 - $4.92 $5,009 - $9,028	-1,835 Reduced 83.79%	355 $1,000
Q2 2022 Aug 15, 2022	BUY	$2.8 - $7.67 $6,132 - $16,797	2,190 New	2,190 $7,000
Q3 2021 Nov 15, 2021	SELL	$5.04 - $8.73 $23,214 - $40,210	-4,606 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$6.58 - $10.66 $17,088 - $27,684	2,597 Added 129.27%	4,606 $31,000
Q1 2021 May 17, 2021	BUY	$6.73 - $13.87 $13,520 - $27,864	2,009 New	2,009 $21,000
Q4 2020 Feb 16, 2021	SELL	$6.37 - $10.33 $10,459 - $16,961	-1,642 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$4.58 - $10.95 $7,520 - $17,979	1,642 New	1,642 $13,000
Q1 2020 May 15, 2020	SELL	$2.91 - $8.7 $2,528 - $7,560	-869 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$2.81 - $9.21 $2,441 - $8,003	869 New	869 $8,000
Q2 2018 Aug 14, 2018	SELL	$7.27 - $21.88 $239 - $722	-33 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$13.4 - $28.4 $442 - $937	33 New	33 $1,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.